Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlobeImmune, a developer of therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases, has reported positive results of GI-4000 and GI-6207 vaccines.
Subscribe to our email newsletter
GI-4000 and GI-6207 vaccines are used to target mutated versions of the Ras oncoprotein and CEA expressing tumors respectively.
In the first study, GI-4000, a series of Tarmogen products engineered to express the seven most common KRAS mutations, was administered as a first line therapy to patients with stage I-III non-small cell lung cancer (NSCLC) having a matching KRAS mutation in their tumor.
GI-6207 is a Tarmogen designed to elicit a T cell immune response in patients against cancers that express carcinoembryonic antigen (CEA).
The primary endpoints of the trials were safety and immunogenicity.
GlobeImmune CMO David Apelian said based on these data, they are designing Phase 2 studies to specifically develop these products for a variety of different clinical indications.